Shanjin Capital

GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative pharmaceuticals and antibody drugs that target various cancer systems. Its efforts are directed at reactivating tumor-specific immune responses and mobilizing the body's own immune system to combat cancer. GenFleet Therapeutics serves both domestic and international markets, contributing to advancements in cancer therapy through its development of signal transduction regulators, tumor microenvironment modulators, and transcription factors.

Nenghua Microelectronics is a gallium nitride power device and chip developer. The company's products include epitaxial wafers, diodes, power devices, chips and modules, etc.; in addition, the company also involves laser stripping, MOCVD bakeware cleaning, HAST coating and other businesses And to provide compound semiconductor users with foundry services in the field of research and development.

Bailian.ai is an artificial intelligence company based in Beijing, China, founded in 2018. It specializes in intelligent customer service and focuses on transforming unstructured business information from the Internet into structured sales leads, thereby enhancing customer efficiency and reducing acquisition costs. The company develops advanced automated knowledge generation technology that employs deep learning to collect, clean, extract, screen, and rewrite business information. This process refines data into precise and trustworthy knowledge, ultimately improving business awareness. Leveraging natural language processing, image recognition, and knowledge graphs, Bailian.ai's solutions facilitate effective processing of market insights and the sourcing of potential customers, thereby optimizing the entire marketing process for businesses.

GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative pharmaceuticals and antibody drugs that target various cancer systems. Its efforts are directed at reactivating tumor-specific immune responses and mobilizing the body's own immune system to combat cancer. GenFleet Therapeutics serves both domestic and international markets, contributing to advancements in cancer therapy through its development of signal transduction regulators, tumor microenvironment modulators, and transcription factors.